Compound ID | 1869
Synonym(s): Sulopenem etzadroxil | CP-70,429 | CP-65,207
Class: Beta-lactam (penem)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. Less active than carbapenems against Gram-negative bacteria, no activity against Pseudomonas aeruginosa |
| Description: | Synthetic compound, fixed combination with probenicid. Oral and iv formulation,not non-inferior to ertapenem in a Phase 3 clinical study in complicated intraabdominal infections and not non-inferior to ciprofloxacin in treatment of uUTI |
| Institute where first reported: | Pfizer, Iterum |
| Year first mentioned: | 1989 |
| Highest developmental phase: | Approved by FDA in 2024 |
| Development status: | Approved |
| Chemical structure(s): | |||||||||||
|
|